Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver

Biochemical Pharmacology

Volumn 52, Issue 10, 1996, Pages 1561-1568

  Hellriegel, Edward T ^a   Matwyshyn, George A ^b   Fei, Peiwen ^a   Dragnev, Konstantin H ^c   Nims, Raymond W ^c   Lubet, Ronald A ^c   Kong, Ah Ng Tony ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

chemoprevention; cytochrome P450; epoxide hydrolase; glutathione S transferase; mRNA gene regulation; rat liver; sulfotransferase; tamoxifen; UDP glucuronosyltransferase

Indexed keywords

CYTOCHROME P450; EPOXIDE HYDROLASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; PHENOBARBITAL; SULFOTRANSFERASE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; LIVER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RNA ANALYSIS;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; LIVER; MALE; RATS; RATS, INBRED F344; RNA, MESSENGER; SULFOTRANSFERASES; TAMOXIFEN;

EID: 0030598422     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00560-6     Document Type: Article

References (53)

1. 1. Harris JR, Lippman ME, Veronesi U and Willett W, Breast cancer. N Engl J Med 327: 473-480, 1992.
2. 2. Jordan VC, The development of tamoxifen for breast cancer therapy. Breast Cancer Res Treat 11: 197-209, 1988.
3. 3. Sharma S, Stutzman JD, Kellof GJ and Steele VE, Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 54: 5848-5855, 1994.
4. 4. Bhimani RS, Troll W, Grunberger D and Frenkel K, Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res 53: 4528-4533, 1993.
5. 5. Lippman SM, Benner SE and Hong WK, Chemoprevention. Strategies for the control of cancer. Cancer 72: 984-990, 1993.
6. 6. Gottardis MM and Jordan VC, Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020-4024, 1987.
7. 7. Fisher B and Redmond C, New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 83: 1278-1280, 1991.
8. 8. Raloff J, Tamoxifen quandary. Sci News 141: 266-269, 1992.
9. 9. Heel RC, Brogden RN, Speight TM and Avery GS, Tamoxifen: A review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16: 1-24, 1978.
10. 10. Sunderland MC and Osborne CK, Tamoxifen in premenopausal patients with metastatic breast cancer: A review. J Clin Oncol 9: 1283-1297, 1991.
11. 11. Buckley M and Goa KL, Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37: 451-490, 1989.
12. 12. Wattenberg LW, Inhibition of carcinogenic and toxic effects of polycyclic hydrocarbons by phenolic antioxidants and ethoxyquin. J Natl Cancer Inst 48: 1425-1430, 1972.
13. 13. Prochaska HJ, De Long MJ and Talalay P, On the mechanisms of induction of cancer-protective enzymes: A unifying proposal. Proc Natl Acad Sci USA 82: 8232-8236, 1985.
14. 14. Zhang Y, Kensler TW, Cho C, Posner GH and Talalay P, Anticarcinogenic activities of sulforaphane and structurally related synthetic norbomyl isothiocyanates. Proc Natl Acad Sci USA 91: 3147-3150, 1994.
15. 15. Bradlow HL, Michnovicz JJ, Telang NT and Osborne MP, Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12: 1571-1574, 1991.
16. 16. Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, Dragnev KH, Kelloff GJ and Lubet RL, Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15: 709-716, 1995.
17. 17. Williams GM, Iatropoulos MJ, Djordjevic MV and Kaltenberg OP, The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14: 315-317, 1993.
18. 18. Han X and Liehr JG, Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363, 1992.
19. 19. White IN, Davies A, Smith LL, Dawson S and De Matteis F, Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem Pharmacol 45: 21-30, 1993.
20. 20. Dragan YP, Xu Y-D and Pitot HC, Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocyte. Prev Med 20: 15-26, 1991.
21. 21. Mulder GJ and Jakoby WB, Sulfation: In: Conjugation Reactions in Drug Metabolism (Ed. Mulder GJ), pp. 107-161. Taylor & Francis, London, 1990.
22. 22. Mulder GJ, Coughtrie MWH and Burchell B, Glucuronidation. In: Conjugation Reactions in Drug Metabolism (Ed. Mulder GJ), pp. 51-106. Taylor & Francis, London, 1990.
23. 23. Ketterer B and Mulder GJ, Glutathione conjugation. In: Conjugation Reactions in Drug Metabolism (Ed, Mulder GJ), pp. 307-364-Taylor & Francis, London, 1990.
24. 24. Guenthner TM, Epoxide hydrolases. In: Conjugation Reactions in Drug Metabolism (Ed. Mulder GJ), pp. 365-404. Taylor & Francis, London, 1990.
25. 25. Chomczynski P and Sacchi N, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
26. 26. Demyan WF, Song CS, Kim DS, Her S, Gallwitz W, Rao TR, Slomczynska M, Chatterjee B and Roy AK, Estrogen sulfotransferase of the rat liver: Complementary DNA cloning and age-and sex-specific regulation of messenger RNA. Mol Endocrinol 6: 589-597, 1992.
27. 27. Nagata K, Ozawa S, Miyata M, Shimada M, Gong D-W, Yamazoc Y and Kato R, Isolation and expression of a cDNA encoding a male-specific rat sulfotransferase that catalyzes activation of N-hydroxy-2-acetylaminofluorene. J Biol Chem 268: 24720-24725, 1993.
28. 28. Ogura K, Kajita J, Narihata H, Watabe T, Ozawa S, Nagata K, Yamazoe Y and Kato R, cDNA cloning of the hydroxy-steroid sulfotransferase STa sharing a strong homology in amino acid sequence with the senescence marker protein SMP-2 in rat livers. Biochem Biophys Res Commun 166: 1494-1500, 1990.
29. pi) from mouse liver. Biochim Biophys Acta 1171: 315-318, 1993.
30. br/p). Pharm Res 10: 461-465, 1993.
31. 31. Kimura T and Owens IS, Mouse UDP glucuronosyltransferase: cDNA and complete amino acid sequence and regulation. Eur J Biochem 168: 515-521, 1987.
32. 32. Ding VD-H, Cameron R and Pickett CB, Regulation of microsomal, xenobiotic epoxide hydrolase messenger RNA in persistent hepatocyte nodules and hepatomas induced by chemical carcinogens. Cancer Res 50: 256-260, 1990.
33. 33. Nims RW, Sinclair PR, Sinclair JF, Dragnev KH, Jones CR, Mellini DW, Thomas PE and Lubet RA, Dose-response relationships for the induction of P450 by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBPO) in rat and cultured rat hepatocytes. Xenobiotica 23: 1411-1426, 1993.
34. al) of sulfotransferase from human liver. Biochem Biophys Res Commun 187: 448-454, 1992.
35. 35. Pickett CB, Telakowski-Hopkins CA, Ding GJ-F, Argenbright L and Lu AYH, Rat liver glutathione S-transferases: Complete nucleotide sequence of a glutathione S-transferase mRNA and the regulation of the Ya, Yb, and Yc mRNAs by 3-methylcholanthrene and phenobarbital. J Biol Chem 259: 5182-5188, 1984.
36. 36. Burchell B, Nebert DW, Nelson DR, Bock KW, Iyanagi T, Jansen PLM, Lancet D, Mulder GJ, Roy Chowdhury J, Siest G, Tephly TR and Mackenzie PI, The UDP glucuronosyl-transferase gene superfamily: Suggested nomenclature based on evolutionary divergence. DNA Cell Biol 10: 487-494, 1991.
37. 37. Wattenberg LW, Prevention-therapy-basic science and the resolution of the cancer problem: Presidential address. Cancer Res 53: 5890-5896, 1993.
38. 38. Yang CS, Smith TJ and Hong JY, Cytochrome P450 enzymes as targets for chemoprevention against chemical carcinogenesis and toxicity: Opportunities and limitations. Cancer Res 54: 1982s-1986s, 1994.
39. 2 to rat liver DNA and ribosomal RNA in vivo. Cancer Res 37: 172-181, 1977.
40. 1-metabolizing aldehyde reductase and glutathione S-transferase by chemoprotectors. Biochem J 300: 117-124, 1994.
41. 41. Lubet RA, Dragnev KH, Chauhan DP, Nims RW, Diwan BA, Ward JM, Jones CR, Rice JM and Miller MS, A pleiotropic response to phenobarbital-type enzyme inducers in the F344/NCr rat. Effects of chemicals of varied structure. Biochem Pharmacol 43: 1067-1078, 1992.
42. 42. Rice JR, Diwan BA, Hu H, Ward JM, Nims RW and Lubet RA, Enhancement of hepatocarcinogenesis and induction of specific cytochrorne P450 dependent monooxygenase activities by the barbiturates allobarbital, aprobarbital, pentobarbital, secobarbital and 5-phenyl and 5-ethyl barbituric acids. Carcinogenesis 15: 395-402, 1994.
43. 450b its relationship to liver tumor promotion. J Am Coll Toxicol 8: 259-268, 1989.
44. 44. Nuwaysir EF, Dragan YP, Jefcoate CR, Jordan VC and Pitot HC, Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res 55: 1780-1786, 1995.
45. 45. Mani C, Pearce R, Parkinson A and Kupfer D, Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 15: 2715-2720, 1994.
46. 46. Berry M, Metzger D and Chambon P, Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 9: 2811-2818, 1990.
47. 47. Huynh HT and Pollak M, Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res, 53: 5585-5588, 1993.
48. 48. Albert JL, Sundstrom SA and Lyttle CR, Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Res 50: 3306-3310, 1990.
49. 49. Sundstrom SA, Komm BS, Xu Q, Boundy V and Lyttle CR, The stimulation of uterine complement component C3 gene expression by antiestrogens. Endocrinology 126: 1449-1456, 1990.
50. 50. Jamil A, Croxtall JD and White JO, The effect of antioestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J Mol Endocrinol 6: 215-221, 1991.
51. 51. Webb P, Lopez GN, Uht RM and Kushner PJ, Tamoxifen activation of the estrogen/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-456, 1995.
52. 52. Komatsu K, Oeda T and Strott CA, Cloning and sequence analysis of the 5′-flanking region of the estrogen sulfotransferase gene: Steroid response elements and cell-specific nuclear DNA-binding proteins. Biochem Biophys Res Commun 194: 1297-1304, 1993.
53. 53. Rushmore TH and Pickett CB, Transcription regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J Biol Chem 265: 14648-14653, 1990.